An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease

Objective We aimed to evaluate the efficacy and safety of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease. Methods We searched PubMed, Scopus, Ovid, and Web of Science for relevant clinical trials discussing CT-P31 administration for IBD patients either naïve to biologica...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of colorectal disease 2019-10, Vol.34 (10), p.1633-1652
Hauptverfasser:	Ebada, Mahmoud Ahmed, Elmatboly, Abdelmagid M., Ali, Ahmed Said, Ibrahim, Ahmed Mohamed, Fayed, Notila, Faisal, Ahmed Faisal, Alkanj, Souad
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Biosimilar Pharmaceuticals - adverse effects Biosimilar Pharmaceuticals - therapeutic use Care and treatment Clinical trials Colon Complications and side effects Crohn's disease Evidence-based medicine Follow-Up Studies Gastroenterology Hepatology Humans Inflammatory bowel disease Inflammatory bowel diseases Inflammatory Bowel Diseases - drug therapy Infliximab Infliximab - adverse effects Infliximab - therapeutic use Internal Medicine Intestinal Mucosa - drug effects Intestinal Mucosa - pathology Intestine Medicine Medicine & Public Health Meta-analysis Monoclonal antibodies Observational Studies as Topic Proctology Remission Remission Induction Reproducibility of Results Review Surgery Systematic review TNF inhibitors Treatment Outcome Tumor necrosis factor inhibitors Tumor necrosis factor-α Ulcerative colitis Wound Healing - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!